Quest for the right Drug
צפטריאקסון - תרימה 1 גרם CEFTRIAXONE - TRIMA 1G (CEFTRIAXONE AS SODIUM)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-שרירי, תוך-ורידי : I.M, I.V
צורת מינון:
אבקה להמסה להזרקהאינפוזיה : POWDER FOR SOLUTION FOR INJ/INF
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects The most frequently reported adverse reactions for ceftriaxone are eosinophilia, leucopenia, thrombocytopenia, diarrhoea, rash, and hepatic enzymes increased. Data to determine the frequency of ceftriaxone ADRs was derived from clinical trials. The following convention has been used for the classification of frequency: - Very common (≥ 1/10); - Common (≥ 1/100 - < 1/10); - Uncommon (≥ 1/1000 - < 1/100); - Rare (≥ 1/10000 - < 1/1000); - Not known (cannot be estimated from the available data); System Organ Class Common Uncommon Rare Not Knowna Infections and Genital fungal infection Pseudomembranous colitisb Superinfectionb infestations Blood and lymphatic Eosinophilia Granulocytopenia Haemolytic anaemiab system disorders Leucopenia Anaemia Agranulocytosis Thrombocytopenia Coagulopathy Immune system Anaphylactic shock disorders Anaphylactic reaction Anaphylactoid reaction Hypersensitivityb Jarisch-Herxheimer reactionb Nervous system Headache Encephalopathy Convulsion disorders Dizziness Ear and Vertigo labyrinth disorders Respiratory, Bronchospasm thoracic and mediastinal disorders Gastrointestinal Diarrhoeab Nausea PancreatitisbStomatitis disorders Loose stools Vomiting Glossitis Hepatobiliary Hepatic enzyme Gall bladder disorders increased precipitationb Kernicterus Hepatitisc Hepatitis cholestaticb,c Skin and Rash Pruritus Urticaria Stevens Johnson Syndromeb subcutaneous Toxic epidermal necrolysisb tissue disorders Erythema multiform Acute generalised exanthematous Pustulosis Drug reaction with eosinophilia and systemic symptoms (DRESS)b Renal and Haematuria Oliguria urinary Glycosuria Renal precipitation(reversible) disorders General Phlebitis Injection site Oedema disorders and pain Chills administration Pyrexia site conditions Investigations Blood creatinine Coombs test false positiveb increased Galactosaemia test false positiveb Non enzymatic methods for glucose determination false positiveb a Based on post-marketing reports. Since these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency, which is therefore categorised as not known. b See section 4.4 c Usually reversible upon discontinuation of ceftriaxone Infections and infestations Reports of diarrhoea following the use of ceftriaxone may be associated with Clostridium difficile. Appropriate fluid and electrolyte management should be instituted (see section 4.4). Ceftriaxone-calcium salt precipitation Rarely, severe, and in some cases, fatal, adverse reactions have been reported in pre-term and full-term neonates (aged < 28 days) who had been treated with intravenous ceftriaxone and calcium. Precipitations of ceftriaxone-calcium salt have been observed in lung and kidneys post-mortem. The high risk of precipitation in neonates is a result of their low blood volume and the longer half-life of ceftriaxone compared with adults (see sections 4.3, 4.4, and 5.2). Cases of ceftriaxone precipitation in the urinary tract have been reported, mostly in children treated with high doses (e.g. ≥ 80 mg/kg/day or total doses exceeding 10 grams) and who have other risk factors (e.g. dehydration, confinement to bed). This event may be asymptomatic or symptomatic, and may lead to ureteric obstruction and postrenal acute renal failure, but is usually reversible upon discontinuation of ceftriaxone (see section 4.4). Precipitation of ceftriaxone calcium salt in the gallbladder has been observed, primarily in patients treated with doses higher than the recommended standard dose. In children, prospective studies have shown a variable incidence of precipitation with intravenous application - above 30% in some studies. The incidence appears to be lower with slow infusion (20-30 minutes). This effect is usually asymptomatic, but the precipitations have been accompanied by clinical symptoms such as pain, nausea and vomiting in rare cases. Symptomatic treatment is recommended in these cases. Precipitation is usually reversible upon discontinuation of ceftriaxone (see section 4.4). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: https://sideeffects.health.gov.il. You can also report by email to: safety@trima.co.il.
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה מוגבלת לשימוש בבתי חולים או אשפוז יום
רישום
169 65 36258 00
מחיר
0 ₪
מידע נוסף